Inovelon oral suspension available to prescribe

Eisai has launched a liquid version of the antiepileptic, Inovelon (rufinamide).

Rufinamide is contraindicated in patients who have had a previous hypersensitivity reaction to triazole derivatives
Rufinamide is contraindicated in patients who have had a previous hypersensitivity reaction to triazole derivatives

Inovelon (rufinamide) 40mg/ml oral suspension is licensed as an adjunct in the treatment of Lennox-Gastaut syndrome in patients 4 years of age and older.

Dose is determined by the patient’s weight and concomitant use of valproate. The suspension can be interchanged at equal doses with the tablets.

View Inovelon Oral Suspension drug record

Further information: Eisai Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Quadruple therapy should be 'new therapeutic standard' for heart failure, say researchers

Quadruple therapy should be 'new therapeutic standard' for heart failure, say researchers

Treatment with a four-drug regimen incorporating newer...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New guidance for minimising psychological impact of COVID-19 pandemic in primary care patients